【摘要】 目的探讨超选择肝动脉化学药物栓塞 (TACE)联合经皮肝导管选择性门静脉碘油栓塞化学药物 (SPVE)治疗中晚期原发性肝癌 (PHC)的价值。方法将中晚期PHC 2 0 3例随机分成2组 ,对比单纯TACE与TACE加SPVE的治疗效果。结果TACE组和TACE加SPVE组总有效率 [完全缓解与部分缓解 (CR +PR) ]分别为 38%和 5 9% ,差异有显著意义 (P均 <0 0 1)。门静脉癌栓消失或缩小率分别为 19%和 75 % ,差异有显著意义 (P均 <0 0 1)。 0 5、1、2年生存率TACE组分别为 93 1%、6 5 4 %、36 6 % ,TACE加SPVE分别为 10 0 %、95 1%、5 9 8%。两组差异有显著意义(P <0 0 1)。结论TACE加SPVE治疗中晚期PHC优于单纯TACE。更多还原

【Abstract】 Objective To evaluate superselective transcatheter arterial chemoembolization ( TACE) plus selective portal vein embolization (SPVE) and large dose of lipiodol on advanced primary liver carcinoma (PHC).Methods Two hundred and three cases of advanced PHC were randomly divided into group treated with ordinary TACE, and that with TACE +SPVE. Results The response rate (CR+PR) was 38% in TACE group and 59% in TACE+SPVE group (P<0.01).Tumor thrombi shrank or resolved in the portal vein in 19.3% in TACE group and 75% in TACE+SPVE group (P<0.01).The 0.5-、1-and 2-year survival rate was 93.1%、65.4%and 36.6% in TACE group and 100%,95.1% and 59.8% in TACE+SPVEgroup(P<0.01). Conclusions TACE+SPVE for the treatment of PHC is superior to TACE alone.更多还原